Pro-Rata Renounceable Rights Issue
Released
Released
Announcement PDF
B I O S Y S T E M S
®
IMAGION BIOSYSTEMS LIMITED
(ASX: IBX)
25 March 2020
Pro-Rata Renounceable Rights Issue
§
Funds to complete the manufacture of nanoparticle material and initiate a first-in-human
study (where sufficient capital is raised) and for general working capital
§
2-for-5 pro-rata renounceable rights issue at an issue price of $0.01 per share to raise a up
to approximately $2.04 million
§
Discount of 38% to the 30 day VWAP
§
With every New Share, shareholders will receive a free attaching New Option
§
New Options will have Exercise Price of 3.0 cents and a term of three years
§
Shortfall facility to enable applications for additional shares
MELBOURNE — Imagion Biosystems Limited (ASX: IBX, the Company), a company dedicated to
improving healthcare through the earlier detection of cancer, announces a pro-rata renounceable
rights issue (Offer). The purpose of the Offer is to strengthen the balance sheet and ensure the
Company has capital resources to continue its efforts to undertake its first clinical study in HER2
metastatic breast cancer.
“We are approaching a critical milestone with the initiation of our first-in-human study. Successful
completion of this study will provide an inflection point and we expect will unlock the clinical and
commercial potential of our technology. This capital raise ensures we can continue to build on the
progress made over towards reaching this important goal,” said Bob Proulx, Executive Chairman of
Imagion Biosystems.
Under the offer, shareholders will be offered two new shares for every five Imagion shares held as at
Monday, 30 March 2020 (Record Date), together with one attaching New Option, exercisable at $0.03
and expiring three years from issue, for every New Shares subscribed.
Pursuant to the Offer, the Company will issue up to 204,512,879 fully paid ordinary shares in the
capital of the Company (New Shares) (subject to fractional rounding) at an issue price of $0.01 each,
to raise up to $2.04 million (before costs). The entitlement to subscribe for New Shares under the Offer
will be renounceable.
The Offer is open to all eligible shareholders who have a registered address within Australia, New
Zealand or the United States as at the Record Date (Eligible Shareholders). The Company has
determined that it would be unreasonable to extend the Offer to shareholders with a registered
address outside Australia, New Zealand, and the United States (Ineligible Shareholders) having regard
to:
§
the small number of shareholders with addresses in such other countries;
Imagion Biosystems Limited
ACN 616 305 027
Level 8, 555 Bourke Street, Melbourne VIC 3000
www.imagionbiosystems.com
B I O S Y S T E M S
®
§
the number and value of the shares they hold; and
§
the cost to the Company of complying with applicable legal and regulatory requirements in
such other countries.
The Offer will close on 21 April 2020 (unless extended), and eligible shareholders can apply for
shortfall in excess of their entitlement.
The New Shares issued under the Offer will rank equally with the Company’s existing Shares on
issue and the Company will apply for quotation of the New Shares and Options. A Prospectus in
relation to the Offer, together with a personalised entitlement acceptance form, will be sent to
eligible shareholders shortly after the Record Date.
Eligible shareholders should consider the Prospectus in deciding whether to acquire securities
under the Offer, and will need to complete the personalised entitlement and acceptance form that
will accompany the prospectus.
Proposed Timetable
Particulars
1,2
Date (2020)
Lodgement of Prospectus with ASIC and provision of copies to ASX
Wednesday, 25 March 2020
Appendix 3B given to ASX
Wednesday, 25 March 2020
Notice sent to security holders containing information required by
Appendix 3B
Thursday, 26 March 2020
“Ex” date – existing shares are quoted on an ex basis and rights
trading starts on a deferred settlement basis
Friday, 27 March 2020
Record Date
Monday, 30 March 2020
Prospectus and Entitlement and Acceptance Form sent to Eligible
Shareholders
Wednesday, 1 April 2020
Rights trading ends
Tuesday, 14 April 2020
Last Day to extend offer closing date
Thursday, 16 April 2020
Closing Date
2
Tuesday, 21 April 2020
ASX notified of under subscriptions
Thursday, 23 April 2020
Anticipated date for the issue of the Shares
Tuesday, 28 April 2020
Normal trading of shares commences
Wednesday, 29 April 2020
Imagion Biosystems Limited
ACN 616 305 027
Level 8, 555 Bourke Street, Melbourne VIC 3000
www.imagionbiosystems.com
B I O S Y S T E M S
®
Notes:
1
Indicative dates only.
2
Subject to the Listing Rules, the Directors reserve the right to extend the Closing Date for the Offer at their discretion. Any
extension of the Closing Date will have a consequential effect on the anticipated date for issue of the Shares.
This timetable is indicative only and subject to change. Subject to the Corporations Act 2001 (Cth)
and the ASX Listing Rules, the Board reserves the right to vary these dates, including the closing
date of the Offer, without prior notice.
The Company also reserves the right not to proceed with the whole or part of the Offer at any time
prior to the issue date. In that event, application monies will be refunded in full without interest.
Full details of the terms and conditions of the Offer will be contained in the Offer document to be
lodged with ASX and dispatched to Eligible Shareholders in accordance with the timetable set out
above.
This Announcement has been approved by the Board of Imagion Biosystems Ltd.
U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630
Australian Media & Investor Relations:
Kyahn Williamson, WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61-3-9866-4722
Imagion Biosystems Limited
ACN 616 305 027
Level 8, 555 Bourke Street, Melbourne VIC 3000
www.imagionbiosystems.com
B I O S Y S T E M S
®
Imagion Biosystems Limited
ACN 616 305 027
Level 8, 555 Bourke Street, Melbourne VIC 3000
www.imagionbiosystems.com
Share your feedback
Discover